The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people
- 28 March 2008
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (8) , 822-833
- https://doi.org/10.1002/pds.1592
Abstract
Purpose To describe the nationwide pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in the Danish population. Methods All Danish citizens aged 10 or above 1 January 1997 were included in the study. The national prescription registry was used to identify all claimed prescriptions for NSAIDs by the cohort until 2005. By individual‐level‐linkage of nationwide registries, information was acquired concerning hospitalizations, comorbidity, concomitant pharmacotherapy and socioeconomic factors. Results The population consisted of 4 614 807 individuals, of which 2 663 706 (57.8%) claimed at least one prescription for NSAID from 1997 to 2005. Ibuprofen and diclofenac were the most frequently used non‐selective NSAIDs, whereas rofecoxib and celecoxib were the most frequently used selective cyclooxygenase‐2 (COX‐2) inhibitors. The usage was similar across all age groups. Female sex and increasing age was associated with increased use of NSAID. Factors predicting extensive NSAID use were: rheumatic disease (odds ratio (OR) = 1.79, 95% confidence interval (CI): 1.69–1.90), gout agents (allopurinol) (OR = 2.54, CI: 2.44–2.64) and other pain medication (OR = 3.27, CI: 3.23–3.31). NSAIDs were most often prescribed for use for one distinct treatment interval and for a short period (overall inter‐quartile range [IQR]: 9–66 days). High doses were used in a relatively large proportion of the population (8.9% for etodolac to 19.5% for celecoxib) and 54 373 (2.0%) claimed prescriptions for more than one NSAID at the same time. Conclusion NSAIDs were commonly used in the Danish population. Since NSAIDs have been associated with increased cardiovascular risk, further research on the overall risk associated with these drugs on a national scale is needed. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 40 references indexed in Scilit:
- What therapies have replaced rofecoxib in Ireland?British Journal of Clinical Pharmacology, 2007
- Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)PLoS Clinical Trials, 2006
- Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profilePharmacoepidemiology and Drug Safety, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987